Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 6/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MPO | P05164 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | AGXT | P21549 | 2/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28147581 | 0.80 | CYP3A4 (0.45) | CYP3A4L3MBTL1MAOB | |
| SCHEMBL15693830 | 0.79 | ICMT (0.44) | ICMT | |
| SCHEMBL2090788 | 0.79 | ICMT (0.46) | ICMTMPOSLC6A4MAPK8 | |
| SCHEMBL14495394 | 0.79 | P2RX7 (0.47) | ICMTMPOSLC6A4MAOB | |
| SCHEMBL14263434 | 0.78 | RIPK1 (0.47) | CYP3A4L3MBTL1MAOBMAPK8DPP4 | |
| SCHEMBL1699443 | 0.78 | MAOB (0.51) | MAOBIDO1AGXTMAPK8 | |
| SCHEMBL1115269 | 0.78 | MAPK8 (0.52) | ICMTMPOSLC6A4MAOBIDO1 | |
| SCHEMBL30148003 | 0.78 | MAPK8 (0.52) | ICMTMPOSLC6A4MAOBIDO1 | |
| SCHEMBL1115079 | 0.78 | MAPK8 (0.52) | ICMTMPOSLC6A4MAPK8DPP4 | |
| SCHEMBL28037697 | 0.78 | CA3 (0.45) | ICMTMPOSLC6A4MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106986832-A | Vegfr3 inhibitor | 癌症治疗合作研究中心有限公司 | 2017-07-28 | — | — | CN | disclosed |